AstraZeneca (AZN) has struck an obesity drug deal with Chinese company CSPC Pharmaceutical Group (CHJTF) worth up to $18.5B to advance the development of multiple next-generation therapies for obesity ...

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland)The ...

The UK pharmaceutical giant AstraZeneca is doubling down on its commitment to the Chinese drugmaker CSPC Pharmaceutical Group ...

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical ...

Eli Lilly to build $3.5 billion Lehigh Valley complex as demand for weight loss drugs grows ...

AI: How does this technological revolution fit with the pharmaceutical regulators who oversee the pharmaceutical sector at ...

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its ...

Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026 ...

Chinese drugmaker Qilu Pharmaceutical will be responsible for developing metabolic disease drug candidates from Insilico Medicine under a contract with a total value that "approaches" $120 million, ...

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

HANGZHOU CITY, ZHEJIANG, CHINA, January 19, 2026 /EINPresswire.com/ -- With the development of the pharmaceutical and ...